Renasant fell to a downgrade from Raymond James analyst Michael Rose on Wednesday. The firm cut its rating from Strong Buy to Outperform and lowered its price target by 10% to $45, implying 12% downside from Tuesday's close of $40.19. Rose's move follows a broader rotation out of regional banks this week, with peers UBSI, FULT, and FNB all retreating between 0.5% and 1.0% on the session. The consensus price target now stands at $47.71, suggesting the Street remains more constructive than Raymond James. Short interest has climbed to 6.0% of free float, its highest level in a year, amid abundant share availability and a cost to borrow of just 0.42%. The $175 million buyback announced alongside Q3 earnings offers a counter to short positioning.
RNST Raymond James downgrade weighs on regional bank outlook; target cut to $45 from $50.
Renasant fell to a downgrade from Raymond James analyst Michael Rose on Wednesday. The firm cut its rating from Strong Buy to Outperform and lowered its price target by 10% to $45, implying 12% downside from Tuesday's close of $40.19. Rose's move follows a broader rotation out of regional banks this week, with peers UBSI, FULT, and FNB all retreating between 0.5% and 1.0% on the session. The consensus price target now stands at $47.71, suggesting the Street remains more constructive than Raymond James. Short interest has climbed to 6.0% of free float, its highest level in a year, amid abundant share availability and a cost to borrow of just 0.42%. The $175 million buyback announced alongside Q3 earnings offers a counter to short positioning.
Key data as of 3 Nov 2026
RNST Raymond James downgrade weighs on regional bank outlook; target cut to $45 from $50.
Renasant Corporation reports Q3 results today. Options traders are piling into calls while short sellers, having built positions to a one-year high, hold their ground. The put/call ratio sits at 0.037, more than 2.5…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RNST — free to start on ORTEX.
Sign up for free →Open RNST on ORTEX